Your session is about to expire
← Back to Search
Group Language Therapy for Aphasia
N/A
Waitlist Available
Led By Dana Moser, Ph.D
Research Sponsored by University of Arkansas
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosis of adult-onset aphasia
Age 18 years or older
Must not have
No history of major psychiatric illness, cognitive impairment, or neurological disorders such as seizures
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1-week post-intervention
Awards & highlights
No Placebo-Only Group
Summary
This trial will study the effects of group participation on adults with aphasia.
Who is the study for?
This trial is for adults over 18 who were proficient in English before having a stroke that led to aphasia, impacting their language abilities. They must have good enough vision and hearing for assessments but can't join if they had childhood speech issues, major psychiatric illnesses, cognitive impairments, or other neurological disorders.
What is being tested?
The study tests the effectiveness of group sessions focused on improving reading and writing skills in individuals with aphasia due to stroke. Participants will undergo language ability assessments before and after attending weekly 90-minute reading group sessions for an academic semester.
What are the potential side effects?
Since this intervention involves educational activities rather than medical treatments, traditional side effects are not applicable. However, participants may experience fatigue or frustration during the learning process.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I have been diagnosed with aphasia as an adult.
Select...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have no major psychiatric, cognitive, or neurological issues.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1-week post-intervention
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1-week post-intervention
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Reading Comprehension Battery for Aphasia-2 (RCBA-2; LaPointe & Horner, 1998) Scores
Secondary study objectives
Communication Confidence Rating Scale for Aphasia (CCRSA; Babbitt & Cherney, 2010)
Discourse Production Task
Gray Oral Reading Test (GORT; Wiederholt & Bryant, 2012)
+2 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Reading GroupExperimental Treatment1 Intervention
All participants in this group will receive language intervention within weekly group sessions and independent tasks with emphasis on improving reading and writing skills among persons with aphasia.
Find a Location
Who is running the clinical trial?
University of ArkansasLead Sponsor
496 Previous Clinical Trials
150,624 Total Patients Enrolled
Dana Moser, Ph.DPrincipal InvestigatorUniversity of Arkansas
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You did not have trouble speaking or understanding language when you were a child.I have been diagnosed with aphasia as an adult.I have no major psychiatric, cognitive, or neurological issues.I am 18 years old or older.
Research Study Groups:
This trial has the following groups:- Group 1: Reading Group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.